Johan Ärnlöv1, Toralph Ruge, Erik Ingelsson, Anders Larsson, Johan Sundström, Lars Lind. 1. From the Department of Public Health and Caring Sciences/Section of Geriatrics (J.Ä.), Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden (E.I., J.Ä.); Department of Medical Sciences, Uppsala University, Uppsala, Sweden (A.L., J.S., L.L.); School of Health and Social Studies, Dalarna University, Falun, Sweden (J.Ä.); and Department of Surgery, Umea University, Umea, Sweden (T.R.).
Abstract
OBJECTIVE: Experimental data imply that endostatin, a proteolytically cleaved fragment of collagen XVIII, could be involved in the development of cardiovascular disease and cancer. Prospective data concerning the relation between circulating endostatin and mortality are lacking. Accordingly, we aimed to study associations between circulating endostatin and mortality risk. APPROACH AND RESULTS: Serum endostatin was analyzed in 2 community-based cohorts: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS; women 50%, n=931; mean age, 70 years; median follow-up, 7.9 years) and the Uppsala Longitudinal Study of Adult Men (ULSAM; n=748; mean age, 77 years; median follow-up, 9.7 years). During follow-up, 90 participants died in PIVUS (1.28/100 person-years at risk), and 417 participants died in ULSAM (6.7/100 person-years at risk). In multivariable Cox regression models adjusted for age and established cardiovascular risk factors, 1 SD higher ln(serum endostatin level) was associated with a hazard ratio of mortality of 1.39 and 95% confidence interval, 1.26 to 1.53, on average in both cohorts. In the ULSAM cohort, serum endostatin was also associated with cardiovascular mortality (177 deaths; hazard ratio per SD of ln[endostatin] 1.45, 95% confidence interval [1.25-1.71]) and cancer mortality (115 deaths; hazard ratio per SD of ln[endostatin] 1.35, 95% confidence interval [1.10-1.66]). CONCLUSIONS: High serum endostatin was associated with increased mortality risk in 2 independent community-based cohorts of the elderly. Our observational data support the importance of extracellular matrix remodeling in the underlying pathophysiology of cardiovascular disease and cancer.
OBJECTIVE: Experimental data imply that endostatin, a proteolytically cleaved fragment of collagen XVIII, could be involved in the development of cardiovascular disease and cancer. Prospective data concerning the relation between circulating endostatin and mortality are lacking. Accordingly, we aimed to study associations between circulating endostatin and mortality risk. APPROACH AND RESULTS: Serum endostatin was analyzed in 2 community-based cohorts: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS; women 50%, n=931; mean age, 70 years; median follow-up, 7.9 years) and the Uppsala Longitudinal Study of Adult Men (ULSAM; n=748; mean age, 77 years; median follow-up, 9.7 years). During follow-up, 90 participants died in PIVUS (1.28/100 person-years at risk), and 417 participants died in ULSAM (6.7/100 person-years at risk). In multivariable Cox regression models adjusted for age and established cardiovascular risk factors, 1 SD higher ln(serum endostatin level) was associated with a hazard ratio of mortality of 1.39 and 95% confidence interval, 1.26 to 1.53, on average in both cohorts. In the ULSAM cohort, serum endostatin was also associated with cardiovascular mortality (177 deaths; hazard ratio per SD of ln[endostatin] 1.45, 95% confidence interval [1.25-1.71]) and cancer mortality (115 deaths; hazard ratio per SD of ln[endostatin] 1.35, 95% confidence interval [1.10-1.66]). CONCLUSIONS: High serum endostatin was associated with increased mortality risk in 2 independent community-based cohorts of the elderly. Our observational data support the importance of extracellular matrix remodeling in the underlying pathophysiology of cardiovascular disease and cancer.
Authors: Kinsuk Chauhan; Divya Anna Verghese; Veena Rao; Lili Chan; Chirag R Parikh; Steven G Coca; Girish N Nadkarni Journal: Kidney Int Date: 2018-12-24 Impact factor: 10.612
Authors: K Dragsbæk; J S Neergaard; H B Hansen; I Byrjalsen; P Alexandersen; S N Kehlet; A-C Bay-Jensen; C Christiansen; M A Karsdal Journal: EBioMedicine Date: 2015-04-30 Impact factor: 8.143
Authors: Johan Mårtensson; Niklas Jonsson; Neil J Glassford; Max Bell; Claes-Roland Martling; Rinaldo Bellomo; Anders Larsson Journal: Ann Intensive Care Date: 2016-01-13 Impact factor: 6.925
Authors: Nicholas Willumsen; Cecilie L Bager; Stephanie N Kehlet; Katrine Dragsbaek; Jesper S Neergaard; Henrik B Hansen; Anne-Christine Bay-Jensen; Diana J Leeming; Allan Lipton; Claus Christiansen; Morten Karsdal Journal: Oncotarget Date: 2017-02-11
Authors: Per Winkel; Janus Christian Jakobsen; Jørgen Hilden; Gorm Boje Jensen; Erik Kjøller; Ahmad Sajadieh; Jens Kastrup; Hans Jørn Kolmos; Kasper Karmark Iversen; Mette Bjerre; Anders Larsson; Johan Ärnlöv; Christian Gluud Journal: BMJ Open Date: 2020-08-20 Impact factor: 2.692